An MVA vector expressing the latent proteins EBNA1 and LMP2 was successful in eliciting EBV-specific cellular responses in nasopharyngeal carcinoma patients in two clinical trials [75,76]. The gene discussed is PSMB9; the disease is nasopharyngeal carcinoma.